MIME-Version: 1.0
Content-Location: file:///C:/A3894A78/laryngeal-ca-071128.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 11">
<meta name=3DOriginator content=3D"Microsoft Word 11">
<link rel=3DFile-List href=3D"laryngeal-ca-071128_files/filelist.xml">
<link rel=3DEdit-Time-Data href=3D"laryngeal-ca-071128_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Laryngeal Cancer</title>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"country-region"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"State"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PlaceType"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PlaceName"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"City"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"place"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Preferred Customer</o:Author>
  <o:LastAuthor>UTMB</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>30</o:TotalTime>
  <o:LastPrinted>2007-11-28T03:07:00Z</o:LastPrinted>
  <o:Created>2008-04-25T19:10:00Z</o:Created>
  <o:LastSaved>2008-04-25T19:10:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>8095</o:Words>
  <o:Characters>44528</o:Characters>
  <o:Company>tm inc</o:Company>
  <o:Lines>664</o:Lines>
  <o:Paragraphs>148</o:Paragraphs>
  <o:CharactersWithSpaces>52475</o:CharactersWithSpaces>
  <o:Version>11.6568</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:UseWord2002TableStyleRules/>
   <w:UseFELayout/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" LatentStyleCount=3D"156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:"Arial Unicode MS";
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:SimSun;
	mso-fareast-language:ZH-CN;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0pt;
	mso-margin-bottom-alt:auto;
	margin-left:0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:SimSun;
	mso-fareast-language:ZH-CN;}
span.text
	{mso-style-name:text;}
p.GRHeading2, li.GRHeading2, div.GRHeading2
	{mso-style-name:_GR_Heading_2;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:12.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GR-Heading1, li.GR-Heading1, div.GR-Heading1
	{mso-style-name:_GR-Heading_1;
	mso-style-parent:"";
	mso-style-next:Normal;
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	mso-pagination:lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GR-NormalChar, li.GR-NormalChar, div.GR-NormalChar
	{mso-style-name:"_GR-Normal Char";
	mso-style-parent:"";
	mso-style-link:"_GR-Normal Char Char";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	mso-hyphenate:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:SimSun;
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
span.GR-NormalCharChar
	{mso-style-name:"_GR-Normal Char Char";
	mso-style-locked:yes;
	mso-style-link:"_GR-Normal Char";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:SimSun;
	mso-fareast-font-family:SimSun;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	mso-bidi-language:AR-SA;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRCLEARFMT, li.GRCLEARFMT, div.GRCLEARFMT
	{mso-style-name:_GR_CLEAR_FMT;
	mso-style-parent:"";
	mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.GRHeading3, li.GRHeading3, div.GRHeading3
	{mso-style-name:_GR_Heading_3;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:6.0pt;
	margin-left:0pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	mso-hyphenate:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.GR-No-Indent-Normal, li.GR-No-Indent-Normal, div.GR-No-Indent-Normal
	{mso-style-name:_GR-No-Indent-Normal;
	mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:none;
	mso-hyphenate:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRIndent-Normal, li.GRIndent-Normal, div.GRIndent-Normal
	{mso-style-name:_GR_Indent-Normal;
	mso-style-parent:_GR-No-Indent-Normal;
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	mso-hyphenate:none;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRTitle, li.GRTitle, div.GRTitle
	{mso-style-name:_GR_Title;
	mso-style-parent:"";
	mso-style-link:"_GR_Title Char";
	mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.GRTitleChar
	{mso-style-name:"_GR_Title Char";
	mso-style-locked:yes;
	mso-style-link:_GR_Title;
	mso-ansi-font-size:14.0pt;
	mso-ansi-language:EN-US;
	mso-fareast-language:EN-US;
	mso-bidi-language:AR-SA;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.GR-Normal, li.GR-Normal, div.GR-Normal
	{mso-style-name:_GR-Normal;
	mso-style-parent:"";
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:12.0pt;
	margin-left:0pt;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	mso-hyphenate:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:bold;
	mso-bidi-font-style:italic;}
p.GRArial10B, li.GRArial10B, div.GRArial10B
	{mso-style-name:_GR_Arial_10B;
	mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
@page Section1
	{size:612.0pt 792.0pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:36.0pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:42215851;
	mso-list-type:hybrid;
	mso-list-template-ids:1724031892 67698705 67698713 67698715 67698703 67698=
713 67698715 67698703 67698713 67698715;}
@list l0:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:299968869;
	mso-list-type:hybrid;
	mso-list-template-ids:478198826 929476620 1338046856 1912355258 84736312 -=
2103400818 566385634 2129444886 -1573878626 911909862;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F06E;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2
	{mso-list-id:727805566;
	mso-list-type:hybrid;
	mso-list-template-ids:1265508880 67698705 67698713 67698715 67698703 67698=
713 67698715 67698703 67698713 67698715;}
@list l2:level1
	{mso-level-text:"%1\)";
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0pt;}
ul
	{margin-bottom:0pt;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0pt 5.4pt 0pt 5.4pt;
	mso-para-margin:0pt;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3Dpurple style=3D'tab-interval:36.0pt'>

<div class=3DSection1>

<p class=3DGRTitle>TITLE: Laser Surgery for Laryngeal Cancer<br>
SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology<br>
DATE: November 28, 2007<br>
RESIDENT PHYSICIAN: <st1:place w:st=3D"on"><st1:City w:st=3D"on">Camysha Wr=
ight</st1:City>,
 <st1:State w:st=3D"on">MD</st1:State></st1:place><br>
FACULTY PHYSICIAN: Michael Underbrink<br>
SERIES EDITORS: Francis B. Quinn, Jr., MD</p>

<div class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><i><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt'>

<hr size=3D2 width=3D"100%" align=3Dcenter>

</span></i></div>

<p class=3DMsoNormal><i><span style=3D'font-size:10.0pt;mso-bidi-font-size:=
12.0pt'>&quot;This
material was prepared by resident physicians in partial fulfillment of
educational requirements established for the Postgraduate Training Program =
of
the UTMB Department of Otolaryngology/Head and Neck Surgery and was not
intended for clinical use in its present form. It was prepared for the purp=
ose
of stimulating group discussion in a conference setting. No warranties, eit=
her
express or implied, are made with respect to its accuracy, completeness, or
timeliness. The material does not necessarily reflect the current or past
opinions of members of the UTMB faculty and should not be used for purposes=
 of
diagnosis or treatment without consulting appropriate literature sources and
informed professional opinion.&quot; <o:p></o:p></span></i></p>

<div class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><i><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt'>

<hr size=3D2 width=3D"100%" align=3Dcenter>

</span></i></div>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DGR-Heading1>Introduction</p>

<p class=3DGRIndent-Normal>Voice-sparing treatment options for early glottic
carcinoma include endoscopic surgical excision, thyrotomy with cordectomy,
hemilaryngectomy, vertical partial laryngectomy with laryngoplasty,
supracricoid partial laryngectomy, and radiation therapy.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Similarly, for supraglottic lesion=
s,
endoscopic resection, open supraglottic laryngectomy, and radiation therapy=
 are
treatment options.<span style=3D'mso-spacerun:yes'>&nbsp; </span></p>

<p class=3DGRIndent-Normal>Conservation laryngeal surgery refers to any pro=
cedure
that maintains physiologic speech and swallow function without the need for=
 a
permanent tracheostoma.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The g=
oal in
conservation laryngeal surgery is to preserve maximum laryngeal function
without compromising the cure rate.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>In other words, complete removal of all malignant disease should be
achieved while preserving the 4 basic functions of the larynx:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>deglutition, respiration, phonatio=
n, and
airway protection.</p>

<p class=3DGRIndent-Normal>Regardless of the specific conservation laryngeal
procedure, a few key principles must be respected.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>First, one must be able to confide=
ntly
predict the extent of tumor, for it is the extent of tumor, and NOT the
T-stage, that determines eligibility for organ preservation surgery.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Involvement of the cricoarytenoid =
joint
is a contraindication to any organ preservation surgery.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Furthermore, it is vitally importa=
nt to
assess subglottic extent at the time of endoscopy.</p>

<p class=3DGRIndent-Normal>Second, the cricoarytenoid unit, and not the true
vocal cord (TVC), is the basic functional unit of the larynx; it is the
cricoarytenoid unit that makes conservation laryngeal surgery possible.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>As long as one cricoarytenoid unit=
 can be
preserved, the patient is a potential candidate for organ preservation
laryngeal surgery.</p>

<p class=3DGRIndent-Normal>Third, resection of normal tissue in organ
preservation surgery is necessary to achieve consistent functional outcomes=
.</p>

<p class=3DGRIndent-Normal>Fourth, it is impossible to know the extent of
submucosal tumor involvement preoperatively.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>For this reason, even the most con=
fident
surgeon must consent his or her patient for a total laryngectomy in additio=
n to
the intended procedure.</p>

<p class=3DGR-Heading1>Anatomy</p>

<p class=3DGRIndent-Normal>Lymphatic drainage of the larynx is sparse anter=
iorly
and at the level of the glottis.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>The lymphatic drainage is richer in the supraglottic and subglottic
regions, as well as the posterior &frac12; of the larynx.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Lesions above the level of the true
vocal cords drain superiorly, while glottic and subglottic lesions drain
inferiorly.</p>

<p class=3DGRIndent-Normal>Laryngeal cancer arises from the TVCs approximat=
ely
75% of the time.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Three fibroe=
lastic
membranes serve as the major barriers to the spread of cancer from (and to)=
 the
glottic region: the conus elasticus inferiorly, the quadrangular membrane
laterally, and the thyrohyoid membrane superiorly.<span
style=3D'mso-spacerun:yes'>&nbsp; </span><i>Broyles&#8217; Tendon</i> is the
insertion of the vocalis tendon into the thyroid cartilage in the area of t=
he
anterior commissure. This is significant because thyroid cartilage
perichondrium is deficient in this area, making it a weak point for the spr=
ead
of malignancy into the thyroid cartilage and on to the extralaryngeal soft
tissues of the neck.</p>

<p class=3DGRIndent-Normal>The cricoarytenoid unit consists of the arytenoid
cartilage, cricoid cartilage, associated musculature, and the superior
laryngeal nerve and recurrent laryngeal nerve for that unit.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Of note, a cricoarytenoid unit may
retain its function despite compromise of the vocal process or superior asp=
ect
of the arytenoid, as long as the body of the arytenoid is preserved.</p>

<p class=3DGR-Heading1>Pathophysiology of Laryngeal Cancer</p>

<p class=3DGRIndent-Normal>Limitation of true vocal cord mobility correlate=
s with
a worsening prognosis, especially if the lesion displays an invasive patter=
n of
growth rather than an exophytic or verrucous one.</p>

<p class=3DGRIndent-Normal>Kirchner described two types of carcinomatous
involvement of the anterior commissure:<span style=3D'mso-spacerun:yes'>&nb=
sp;
</span>early lesions that are not invasive and confined to the level of the
glottis, and those lesions that invade aggressively and spread superiorly to
involve the base of the epiglottis.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>The latter tend to advance within the cancellous framework of the
thyroid cartilage deep to normal appearing soft tissue and imply a poorer
prognosis.</p>

<p class=3DGRIndent-Normal>Approximately &frac14; of early glottic cancer e=
xtends
to the anterior commissure.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Approximately 1/5 of early glottic cancer extends 5 mm or more below=
 the
level of the true vocal cords.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Likewise, 1/5 extends to involve the supraglottic region.</p>

<p class=3DGRIndent-Normal>Early glottic cancer infrequently metastasizes, =
and
when it does, it is almost always to the ipsilateral neck.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Lesions limited to the true vocal =
cords
(e.g., T1 and T2) demonstrate a 5% incidence of cervical metastasis, while =
this
figure jumps to 30-40% for T3 lesions.<span style=3D'mso-spacerun:yes'>&nbs=
p;
</span></p>

<p class=3DGRIndent-Normal>Approximately 95% of glottic neoplasms are squam=
ous
cell carcinoma.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Tumor spread =
is
usually superficial and well visualized.<span style=3D'mso-spacerun:yes'>&n=
bsp;
</span>Skip lesions, like those seen in the hypopharynx, are rare.</p>

<p class=3DGRIndent-Normal>Supraglottic squamous cell carcinoma is a differ=
ent
disease process from its glottic counterpart.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Supraglottic carcinoma exhibits a =
much
higher incidence of occult nodal metastasis and frank nodal metastasis at
presentation.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Furthermore, 19=
% of
survivors will develop a second respiratory tract primary within 5 years.</=
p>

<p class=3DGRIndent-Normal>Supraglottic lesions tend to take a long time to
spread to the glottis and paraglottic space.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>However, epiglottic carcinoma demo=
nstrates
a predilection for preepiglottic space involvement.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>When preepiglottic and paraglottic=
 space
involvement occurs, it usually involves a broad, pushing front with a
pseudocapsule.<span style=3D'mso-spacerun:yes'>&nbsp; </span>This pseudocap=
sule
likely arises from the epiglottic perichondrium and the quadrangular membra=
ne.</p>

<p class=3DGRIndent-Normal>Early suprahyoid epiglottic lesions are unique i=
n that
they rarely invade the preepiglottic space and rarely result in cervical
metastasis <i>unless </i>there is occult tongue base involvement.</p>

<p class=3DGR-Heading1>Background on Lasers</p>

<p class=3DGRIndent-Normal>Laser is an acronym for <i>l</i>ight <i>a</i>mpl=
ification
by the <i>s</i>timulated <i>e</i>mission of <i>r</i>adiation. Einstein<sup>=
<span
style=3D'color:#0066CC'> </span></sup>postulated the theoretical foundation=
 of
laser action, stimulated emission of radiation, in 1917. Einstein postulated
that the spontaneous emission of electromagnetic radiation from an atomic
transition has an enhanced rate in the presence of similar electromagnetic
radiation.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Maiman<sup><span
style=3D'color:#0066CC'> </span></sup>built the first laser in 1960. With
synthetic ruby crystals, this laser produced electromagnetic radiation at a
wavelength of 0.69 &micro;m in the visible range of the spectrum. Although =
the
laser energy produced by Maiman's ruby laser lasted less than 1 ms, it paved
the way for explosive development and widespread application of this
technology.</p>

<p class=3DGRIndent-Normal>Two important advances allowed the laser to be u=
seful
in otolaryngology: (1) in 1965, the carbon dioxide <a
name=3D4-u1.0-B0-323-01985-4..50010-1--p215></a>(co<sub>2</sub>) laser was
developed, and (2) in 1968, Polanyi developed the articulated arm to deliver
the infrared radiation from the co<sub>2</sub> laser to remote targets. He
combined his talents with Jako and used the articulated arm and the co<sub>=
2</sub>
laser in laryngeal surgery. Simpson and Polanyi described the series of
experiments and new instrumentation that made this work possible.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para6>=
</a>A
laser is an electro-optical device that emits organized light (rather than =
the
random-pattern light emitted from a light bulb) in a very narrow intense be=
am
by a process of optical feedback and amplification.</p>

<p class=3DGRIndent-Normal>Electrons can change their orbits, thereby chang=
ing
the energy state of the atom. During excitation, an electron can make the
transition from a low-energy level to a higher energy level. Excitation that
comes from the electron interacting with light (a photon) is termed <i>abso=
rption</i>.
The atom always seeks its lowest energy level (i.e., the ground state).
Therefore, the electron will spontaneously drop from the high-energy level =
back
to the lowest energy level in a very short time (typically 10<sup><span
style=3D'color:#0066CC'>-8</span></sup> sec). As the electron spontaneously=
 drops
from the higher energy level to the lower energy level, the atom must give =
up
the energy difference. The atom emits the extra energy as a photon of light=
 in
a process termed the <i>spontaneous emission of radiation.<o:p></o:p></i></=
p>

<p class=3DGRIndent-Normal>All laser devices have an optical resonating cha=
mber
(cavity) with two mirrors. The space between these mirrors is filled with an
active medium, such as Ar, Nd:YAG, or co<sub>2</sub>. An external energy so=
urce
(e.g., an electric current) excites the active medium within the optical
cavity. This excitation causes many atoms of the active medium to be raised=
 to
a higher energy state. A population inversion occurs when more than half of=
 the
atoms in the resonating chamber have reached a particular excited state.
Spontaneous emission is taking place in all directions. Light (photons) emi=
tted
in the direction of the long axis of the <a
name=3D4-u1.0-B0-323-01985-4..50010-1--p216></a>laser is retained within the
optical cavity by multiple reflections off of the precisely aligned mirrors.
One mirror is completely reflective, and the other is partially transmissiv=
e.
Stimulated emission occurs when a photon interacts with an excited atom in =
the
optical cavity. This yields pairs of identical photons that are of equal
wavelength, frequency, and energy and are in phase with each other. This
process occurs at an increasing rate with each passage of the photons throu=
gh
the active medium.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para14=
></a>With
most surgical lasers, the physician can control three variables: (1) power
(measured in watts); (2) spot size (measured in millimeters); and (3) expos=
ure
time (measured in seconds).<a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec=
5_3"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec5></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para15></a></p>

<p class=3DGRIndent-Normal>Of power, spot size, and exposure time, power is=
 the
least useful variable and may be kept constant with widely varying effects,
depending on the spot size and the duration of exposure. For example, the
relationship between power and depth of tissue injury becomes logarithmic w=
hen
the power and exposure time are kept constant and the spot size is varied.<=
/p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para16=
></a>Irradiance
is a more useful measure of the intensity of the beam at the focal spot than
power is because it considers the surface area of the focal spot. Specifica=
lly,
irradiance is expressed (in W/cm<sup><span style=3D'color:#0066CC'>2</span>=
</sup>)
as: Irradiance =3D Power in the focal spot/Area of the focal spot.</p>

<p class=3DGRIndent-Normal><a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec=
6_3"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec6></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--p217></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para17></a>Power and spot size are
considered together, and a combination is selected to produce the appropria=
te
irradiance. If the exposure time is kept constant, the relationship between
irradiance and depth of injury is linear as the spot size is varied. Irradi=
ance
is the most important operating parameter of a surgical laser at a given
wavelength. Therefore, surgeons should calculate the appropriate irradiance=
 for
each procedure to be performed. These calculations allow the surgeon to
control, in a predictable manner, the tissue effects when changing from one
focal length to another (e.g., from 400 mm for microlaryngeal surgery to 12=
5 mm
for hand-held surgery). Irradiance varies directly with power and inversely
with surface area. This relationship of surface area to beam diameter is
important when evaluating the power density because the larger the surface
area, the lower the irradiance; conversely, the smaller the surface area, t=
he
higher the irradiance. <a name=3D4-u1.0-B0-323-01985-4..50010-1--para18></a=
></p>

<p class=3DGRIndent-Normal>Depth of focus is realized when a camera is focu=
sed.
With a camera, a range of objects is in focus, which can be set without
carefully measuring the distance between the object and the lens. The prece=
ding
equations show that a long focal length lens leads to a large beam waist, w=
hich
also translates as a large depth of focus.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para21=
></a>The
size of the laser beam on the tissue (spot size) can therefore be varied in=
 two
ways: (1) because the minimum beam diameter of the focal spot increases
directly with increasing the focal length of the laser focusing lens, the
surgeon can change the focal length of the lens to obtain a particular beam
diameter. As the focal length decreases, a corresponding decrease occurs in=
 the
size of the focal spot. Also, the smaller the spot size is for any given po=
wer
output, the greater the corresponding power density. (2) The surgeon can al=
so
vary the spot size by working in or out of focus. The minimum beam diameter=
 and
highest power concentration occur at the focal plane, where much of the pre=
cise
cutting and vaporization is carried out.<span style=3D'mso-spacerun:yes'>&n=
bsp;
</span>As the distance from the focal plane increases, the laser beam diver=
ges
or becomes unfocused. The cross-sectional area of the spot increases and th=
us
lowers the power density for a given output. The size of the focal spot dep=
ends
on the focal length of the laser lens and whether the surgeon is working in=
 or
out of focus. </p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para23=
></a>The
surgeon can vary the amount of energy delivered to the target tissue by var=
ying
the exposure time. Fluence refers to the amount of time (measured in second=
s)
that a laser beam irradiates a unit area of tissue at a constant irradiance.
Fluence is a measure, then, of the total amount of laser energy per unit ar=
ea
of exposed target tissue<a name=3D4-u1.0-B0-323-01985-4..50010-1--para24></=
a>.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Fluence varies directly with the l=
ength
of the exposure time, which can be varied by working in the pulsed mode
(duration, 0.05&#8211;0.5 sec) or in the continuous mode.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para25=
></a>When
electromagnetic energy (incident radiation) interacts with tissue, the tiss=
ue
reflects, absorbs, transmits, and scatters portions of the light. The surgi=
cal
interaction of this radiant energy with tissue is caused only by that porti=
on
of light that is absorbed (i.e., the incident radiation minus the sum of the
reflected and transmitted portions).</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para26=
></a>The
actual tissue effects produced by the radiant energy of a laser vary with t=
he
laser's wavelength. Each type of laser exhibits different characteristic
biologic effects on tissue and is therefore useful for different applicatio=
ns.
However, certain similarities exist <a
name=3D4-u1.0-B0-323-01985-4..50010-1--p219></a>regarding the nature of las=
er
light interaction with biologic tissue. The lasers used in medicine and sur=
gery
today can be ultraviolet, meaning the interactions are a complex mixture of
heating and photodissociation of chemical bonds. The more commonly used las=
ers
emit light in the visible or the infrared region of the electromagnetic
spectrum, and their primary form of interaction with biologic tissue leads =
to
heating. Therefore, if the radiant energy of a laser is to exert its effect=
 on
the target tissue, it must be absorbed by the target tissue and converted to
heat. Scattering tends to spread the laser energy over a larger surface are=
a of
tissue, but it limits the penetration depth. The shorter the wavelength of
light, the more it is scattered by the tissue. If the radiant energy is
reflected from or transmitted through the tissue, no effect will occur. To
select the most appropriate laser system for a particular application, the
surgeon should thoroughly understand these characteristics regarding the
interaction of laser light with biologic tissue</p>

<p class=3DGRIndent-Normal>co<sub>2</sub> lasers produce light with a wavel=
ength
of 10.6 &micro;m in the infrared (invisible) range of the electromagnetic
spectrum. A second, built-in, coaxial helium-neon laser is necessary because
its red light indicates the site where the invisible co<sub>2</sub> laser b=
eam
will impact the target tissue. Thus, this laser acts as an aiming beam for =
the
invisible co<sub>2</sub> laser beam. The radiant energy produced by the co<=
sub>2</sub>
laser is strongly absorbed by pure, homogeneous water and by all biologic
tissues high in water content. The extinction length of this wavelength is
about 0.03 mm in water and in soft tissue. Reflection and scattering are
negligible. Because absorption of the radiant energy produced by the co<sub=
>2</sub>
laser is independent of tissue color and because the thermal effects produc=
ed
by this wavelength on adjacent nontarget tissues are minimal, the co<sub>2<=
/sub>
laser has become extremely versatile in otolaryngology.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para43=
></a>With
current technology, light from the co<sub>2</sub> laser cannot be transmitt=
ed
through existing flexible fiberoptic endoscopes, although research and
development of a suitable flexible fiber for transmission of this wavelengt=
h is
being carried out internationally. At present, the radiant energy of this l=
aser
is transmitted from the optical resonating chamber to the target tissue via=
 a
series of mirrors through an articulating arm to the target tissue. The co<=
sub>2</sub>
laser can be used free-hand for macroscopic surgery, attached to the operat=
ing <a
name=3D4-u1.0-B0-323-01985-4..50010-1--p224></a>microscope for microscopic
surgery, and adapted to an endoscopic coupler for bronchoscopic surgery. Th=
is
latter application requires rigid nonfiberoptic bronchoscopes. Pattern
generators coupled with a micromanipulator on the operating microscope have
also been introduced to help with the surgical precision in laryngology.</p>

<p class=3DGR-Heading1>Laser Safety</p>

<p class=3DGRIndent-Normal>The laser is a precise but potentially dangerous
surgical instrument that must be used with caution. Although distinct
advantages are associated with the use of laser surgery in the management of
certain benign and malignant diseases of the upper aerodigestive tract, the=
se
advantages must be weighed against the risks of complications. Because of t=
hese
risks, the surgeon must first determine if the laser offers an advantage ov=
er
conventional surgical techniques. For the surgeon to use good judgment in t=
he
selection and use of lasers in practice, prior experience in laser surgery =
is
necessary. <a name=3D4-u1.0-B0-323-01985-4..50010-1--para64></a>Hospitals t=
hat
offer laser surgery should appoint a laser safety officer and set up a laser
safety committee consisting of the laser safety officer, physicians using t=
he
laser, anesthesiologists, operating room nurses, a hospital administrator, =
and
a biomedical engineer. The purpose of this committee is to develop policies=
 and
procedures for the safe use of lasers within the hospital<a
name=3D4-u1.0-B0-323-01985-4..50010-1--para65></a></p>

<p class=3DGRIndent-Normal>Several structures of the eye are at risk. The a=
rea of
injury usually depends on which structure absorbs the most radiant energy p=
er
volume of tissue. Depending on the wavelength, corneal or retinal burns, or
both, are possible from acute exposure to the laser beam. The possibility f=
or
corneal or lenticular opacities (cataracts) or retinal injury exists after =
chronic
exposure to excessive levels of laser radiation. Retinal effects occur when=
 the
laser emission wavelength occurs in the visible and near-infrared range of =
the
electromagnetic spectrum (0.4&#8211;1.4 <i>&micro;</i>m). <a
name=3D4-u1.0-B0-323-01985-4..50010-1--para68></a><span
style=3D'mso-spacerun:yes'>&nbsp;</span>To reduce the risk of ocular damage
during cases involving the laser, certain precautions should be followed.
Protecting the eyes of the patient, surgeon, and other operating room perso=
nnel
must be addressed. The actual protective device will vary according to the
wavelength of the laser used. A sign should be placed outside the operating
room door warning all persons entering the room to wear protective glasses
because the laser is in use. In addition, extra glasses for the specific
wavelength in use should be placed on a table immediately outside the room.=
 The
doors to the operating room should remain closed during laser use.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para69=
></a>Patients
undergoing co<sub>2</sub> laser surgery of the upper aerodigestive tract sh=
ould
have a double layer of saline-moistened eye pads placed over the eyes.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>All operating room personnel shoul=
d wear
protective eyeglasses with side protectors. Regular eyeglasses or contact
lenses protect only the areas covered by the lens and do not provide protec=
tion
from possible entry of the laser beam from the side. When working with the
operating microscope and the co<sub>2</sub> laser, the surgeon need not wear
protective glasses. The optics of the microscope provide the necessary
protection. When working with the Nd:YAG laser, all operating room personnel
(and the patient) must wear wavelength-specific protective eyeglasses that =
are
usually blue-green. Although the beam direction and point of impact may app=
ear
to be confined within the endoscope, inadvertent deflection of the beam may
occur because of a faulty contact, a break in the fiber, or accidental
disconnection between the fiber and endoscope. Special wavelength-specific
filters are available for flexible and rigid bronchoscopes. When these filt=
ers
are in place, the surgeon need not wear protective eyeglasses.</p>

<p class=3DGRIndent-Normal>When working with the Ar, KTP, or dye lasers, all
personnel in the operating room, including the patient, should again wear
wavelength-specific protective eyeglasses that are usually amber. When
undergoing photocoagulation for selected cutaneous vascular lesions of the
face, the patient usually wears protective metal eye shields rather than
protective eyeglasses. Similar precautions are necessary for the visible and
near-infrared wavelength lasers. The major difference is the type of eye
protection that is worn.</p>

<p class=3DGRIndent-Normal><a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec=
27_"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec27></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para71></a>The patient's exposed ski=
n and
mucous membranes outside the surgical field should be protected by a double
layer of saline-saturated surgical towels, surgical sponges, or lap pads. W=
hen
microlaryngeal laser surgery is being performed, the beam might partially
reflect off the proximal rim of the laryngoscope rather than go down it. Th=
us,
saline-saturated surgical towels completely drape the patient's face. Only =
the
proximal lumen of the laryngoscope is exposed. Great care must be exercised=
 to
keep the wet draping from drying out. It should occasionally be moistened
during the procedure. Teeth in the operative field also need to be protecte=
d.
Saline-saturated Telfa, surgical sponges, or specially constructed metal de=
ntal
impression trays can be used. Meticulous attention is paid to the protective
draping procedures at the beginning of the surgery. The same attention shou=
ld
be paid to the <a name=3D4-u1.0-B0-323-01985-4..50010-1--p228></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--p229></a>continued protection of the=
 skin
and teeth during the surgical procedure.</p>

<p class=3DGRIndent-Normal><a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec=
28_"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec28></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para72></a>Two separate suction setu=
ps
should be available for all laser cases in the upper aerodigestive tract. O=
ne
provides for adequate smoke and steam evacuation from the operative field;
whereas the second is connected to the surgical suction tip for the aspirat=
ion
of blood and mucus from the operative wound. When performing laser surgery =
with
a closed anesthetic system, the surgeon should use constant suctioning to
remove laser-induced smoke from the operating room. This helps to prevent
inhalation by the patient, surgeon, and operating room personnel. When the
anesthetic system is open or has jet ventilation systems, suctioning should=
 be
intermittent to maintain the forced inspiratory oxygen at a safe level.
Laryngoscopes, bronchoscopes, operating platforms, mirrors, and anterior
commissure and ventricle retractors with built-in smoke-evacuating channels=
 facilitate
the evacuation of smoke from the operative field. </p>

<p class=3DGR-Heading1><a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec29_"=
></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec29></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para74></a>Complications</p>

<p class=3DGRIndent-Normal>Aside from a few minor eye injuries from a laser=
 beam
exposure, most serious accidental injuries related to laser use can be trac=
ed
to the ignition of surgical drapes and airway tubes.<sup><span
style=3D'color:#0066CC'>[<a
href=3D"http://www.mdconsult.com.libux.utmb.edu/das/book/body/82435597-3/0/=
1263/74.html#4-u1.0-B0-323-01985-4..50010-1--bib41"><span
style=3D'color:#0066CC'>41</span></a>]</span></sup> Because the anesthesiol=
ogist
is also concerned with the airway and because potent oxidizing gases pass
through the airway in close approximation to the path of the laser beam, it=
 is
necessary to develop a team approach to the anesthetic management of the
patient undergoing laser surgery of the upper aerodigestive tract. It is
recommended that anesthesiologists involved with laser surgery cases attend=
 a
didactic session devoted to this subject. Finally, the operating room staff
must be educated with regard to laser surgery. Attendance at an inservice
workshop with exposure to clinical laser biophysics and the basic workings =
of
the laser, as <a name=3D4-u1.0-B0-323-01985-4..50010-1--p227></a>well as ha=
nds-on
orientation should be the minimal requirement for nurses to participate in
laser surgery.</p>

<p class=3DGRIndent-Normal>One of the most devastating complications of las=
er
surgery of the aerodigestive tract is endotracheal tube ignition and result=
ing
injury to the laryngotracheal mucosa. At present, a nonflammable, universal=
ly
accepted endotracheal tube for all types of laser surgery of the upper
aerodigestive tract does not exist. The traditional polyvinyl endotracheal =
tube
should not be used, either wrapped or unwrapped. It offers the least resist=
ance
to penetration by the laser beam of all the endotracheal tubes that have be=
en
tested, fire-breakdown products are toxic, and tissue destruction associated
with combustion of this tube is the most severe. Endotracheal tubes for las=
er
surgery that are wavelength specific are now available from several
manufacturers and should be used at all times unless jet ventilation techni=
ques
are used.</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50010-1--para75=
></a>Protection
of the endotracheal tube from direct or reflected laser beam irradiation is=
 of
primary importance. If the laser beam strikes an unprotected endotracheal t=
ube
carrying oxygen, ignition of the tube could result in a catastrophic,
intraluminal, blowtorch-type endotracheal tube fire. Protection should also=
 be provided
for the cuff of the endotracheal tube. Methylene blue-colored saline should=
 be
used to inflate the cuff. Saline-saturated cottonoids are then placed above=
 the
cuff in the subglottic larynx to further protect the cuff. These cottonoids
require frequent moistening during the procedure. If the cuff deflates from=
 an
errant hit by the laser beam, the already saturated cottonoids turn blue to
warn the surgeon of impending danger. The tube should then be removed and
replaced with a new one. Use of the microlaryngeal operating platform offers
further protection against potential danger. Inserted into the subglottic
larynx above the level of the packed cottonoids, this unique instrument ser=
ves
as a back stop to protect the cottonoids, endotracheal tube, and cuff from =
any
direct or reflected laser beam irradiation.</p>

<p class=3DGRIndent-Normal><a name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec=
30_"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec30></a>Complications related to=
 the
use of the CO2 laser in the supraglottis are exceptionally rare.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>The epiglottis is thought to be a
vestigial organ in humans, so swallowing should not be significantly compro=
mised
without it.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Laryngeal protect=
ion is
impaired for several days to 6 weeks depending on the extent of laser
resection.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Patients with a no=
rmal
preoperative swallow do not experience permanent swallowing deficits with l=
aser
resection.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Preexisting swallo=
wing
impairment such as may be seen in stroke or previous head and neck surgery =
is a
relative contraindication to <i>any </i>partial laryngeal resection.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In short, some, but not the majori=
ty of
patients, may require temporary feeding tubes.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>This is so when using the laser be=
cause
the superior laryngeal nerves are not disturbed proximal to the larynx,
laryngeal elevation is not impaired by a tracheotomy or disturbance of the
suprahyoid musculature, and healing by secondary fibrosis and epithelializa=
tion
results in a favorable cicatrisation that produces a new supraglottic valve=
.</p>

<p class=3DGRIndent-Normal>In Moreau&#8217;s study granuloma formation at t=
he
anterior commissure was a common occurrence.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>These granulomas tended to last for
several months before spontaneous resolution.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Other complications, which were fe=
w,
included laryngeal hemorrhage, pneumothorax, aspiration pneumonia, subcutan=
eous
air, and prelaryngeal abscess.<span style=3D'mso-spacerun:yes'>&nbsp; </spa=
n>In
addition, several webs resulted from anterior commissure resection; these w=
ere
treated with repeat endoscopic procedures.</p>

<p class=3DGRIndent-Normal>The transoral management of squamous cell carcin=
oma of
the larynx using the co<sub>2</sub> laser is an obvious extension of the
application of this surgical instrument. The advantages of precision, incre=
ased
hemostasis, and decreased intraoperative edema allow the surgeon to perform
exquisitely accurate and relatively bloodless endoscopic surgery of the lar=
ynx.</p>

<p class=3DGRIndent-Normal>A comprehensive report on the <a
name=3D4-u1.0-B0-323-01985-4..50105-2--p2340></a>results of TLM was given by
Steiner and his colleagues at the European Federation of
Oto-Rhino-Laryngological Societies (EUFOS) in <st1:place w:st=3D"on"><st1:C=
ity
 w:st=3D"on">Budapest</st1:City></st1:place>. His reports were based on 606
patients treated from 1979 to 1986 in Erlangen-Nurnberg or 1986 to 1993 in
G&ouml;ttingen. The last <st1:place w:st=3D"on"><st1:City w:st=3D"on">Erlan=
gen</st1:City></st1:place>
entry was in January 1994, and the last G&ouml;ttingen entry was in December
1995. The only exclusions were patients with simultaneous second primary
cancers, thus not treatable for cure. Of the patients, 360 had early glottic
cancer, 43 had early supraglottic disease, 147 had late glottic carcinoma, =
and
56 had late supraglottic cancer. The T distributions were pT<sub>is</sub>; =
45
patients, pT<sub>1</sub>; 228 patients, pT<sub>2</sub>; 231 patients, pT3; =
69
patients and pT4; 33. As might be expected, the T<sub>is</sub> and T<sub>1a=
</sub>
cases did extremely well and will receive no further comment.</p>

<p class=3DGRIndent-Normal>Combining the pTis to pT2a patients, there were =
35
recurrent cancers amongst 360 TLMs. Of these 35 recurrences, 5 occurred more
than 5 years after initial treatment (thus possibly were second primaries).=
</p>

<p class=3DGRIndent-Normal><a name=3D4-u1.0-B0-323-01985-4..50105-2--para15=
2></a>Of
the 35 patients, 27 were salvaged by functional surgery, mainly by transoral
laser micro-re-resection. Eight patients proceeded to laryngectomy. Of the =
360
(0.5%), 2 died from the glottic cancer. Six developed neck metastases, 3 wi=
th
their primary controlled and 3 with recurrent cancer at the primary site.
During the course of their follow-up, 23 patients (6.4%) developed second
primaries, and 16 (5%) died of their second primary. The commonest cause of
death in the whole group was intercurrent disease&#8212;64 patients (17.5%).
The 5-year Kaplan-Meier survivals were 87% for the &quot;very early&quot;
glottic group and 83% for the &quot;early&quot; cases. TLM preserved voice =
in
352 of the 360 patients (98%), and was judged to be of satisfactory quality=
 in
90%. One patient bled. No one needed a tracheotomy.</p>

<p class=3DGR-Heading1>Endoscopic Management of Glottic Lesions</p>

<p class=3DGRIndent-Normal>For CIS, T1a, and T1b glottic carcinoma, there a=
re
essentially three treatment options:<span style=3D'mso-spacerun:yes'>&nbsp;
</span>conservation surgery, radiation therapy, and microendoscopic CO2 las=
er
excision.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The cure rates for =
all
three of these options are approximately equal. </p>

<p class=3DGRIndent-Normal>Regardless of treatment modality (laser excision
versus XRT), local control is approximately 94% for T1a lesions, 71% for T1b
lesions, and 83% for T2 lesions.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>This indicates that anterior commissure involvement (e.g., T1b lesio=
ns)
portends a worse prognosis for laryngeal conservation regardless of treatme=
nt
modality.<span style=3D'mso-spacerun:yes'>&nbsp; </span>In the <st1:place w=
:st=3D"on"><st1:country-region
 w:st=3D"on">US</st1:country-region></st1:place>, vertical partial laryngec=
tomy
is favored over the laser or XRT for T2 lesions involving the anterior
commissure or arytenoid.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Tumor
features that predict a poor response to XRT and favor use of the laser inc=
lude
increased tumor bulk and overexpression of P53.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>One tumor factor that predicts a p=
oor
result with laser excision is a history of previous XRT.</p>

<p class=3DGRIndent-Normal>There are essentially 3 minimally invasive surgi=
cal
treatment options for early glottic cancer:<span
style=3D'mso-spacerun:yes'>&nbsp; </span>cold instrumentation, powered
instrumentation, and transoral laser excision.</p>

<p class=3DGRIndent-Normal>Strong and Jako in 1972 introduced CO2 laser exc=
ision
for the treatment of laryngeal disease.<span style=3D'mso-spacerun:yes'>&nb=
sp;
</span>The advantages they noted were precise control, minimal bleeding, and
the absence of post-operative edema.</p>

<p class=3DGRIndent-Normal>Preoperatively, all patients should undergo a th=
orough
physical examination, including flexible laryngoscopy and
videostroboscopy.<span style=3D'mso-spacerun:yes'>&nbsp; </span>It is vital=
ly
important to assess for the presence or absence of a mucosal wave, which
implies the absence or presence of involvement of the vocalis muscle.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>However, injection of 1:10,000
epinephrine pre-excision has proven more reliable than videostrobe at
determining the presence of invasion of the vocal ligament.<span
style=3D'mso-spacerun:yes'>&nbsp; </span><span style=3D'display:none;mso-hi=
de:all'>HoHHO</span>In
addition, <i>any </i>impairment of vibratory patterns of the TVC suggests t=
hat
a submucosal cordectomy, alone, will not be adequate.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Gallo is even more aggressive.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>She recommends a complete cordecto=
my for
involvement of the anterior commissure, any lesion that infiltrates into the
vocal fold, and tumor size &gt;0.7 mm.</p>

<p class=3DGRIndent-Normal>Manual pressure applied by an assistant or silk =
tape
over the neck is often useful to improve visualization, especially at the
anterior commissure.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Microcups
should be used to grasp the lesion, and tension applied. The excision should
then be performed with solitary laser bursts.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Once the cordectomy specimen has b=
een
excised, it should be oriented and then sent to surgical pathology for froz=
en
section.<span style=3D'mso-spacerun:yes'>&nbsp; </span>If a positive margin=
 is
noted, the resection can be extended until healthy margins are obtained.<sp=
an
style=3D'mso-spacerun:yes'>&nbsp; </span>Currently a &#8220;safe&#8221; mar=
gin
for CIS or T1 lesions is considered 2-5 mm of surrounding healthy tissue.</=
p>

<p class=3DGRIndent-Normal>Exclusion criteria should be stricter for endosc=
opic
resection of glottic lesions as compared to open conservation laryngeal
surgery.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Exclusion criteria i=
nclude
deep involvement or fixation of tumor at the anterior commissure, vocal pro=
cess
involvement, involvement of the ventricle (some debate), and subglottic
extension (some debate).<span style=3D'mso-spacerun:yes'>&nbsp; </span>In t=
he
area of the anterior commissure, resection must include thyroid cartilage
because of the absence of perichondrium in this region.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In addition, endoscopic resection =
is
only appropriate when close followup is possible and appropriate adjuvant
therapy is provided when indicated.</p>

<p class=3DGRIndent-Normal>Many authors also regard impaired TVC mobility a=
s a
contraindication to use of the laser; in a series by Steiner, 11 patients w=
ith
T2b lesions who received laser excision and post-op XRT had a 5-year disease
free survival of 67%.<span style=3D'mso-spacerun:yes'>&nbsp; </span>However=
, the <st1:place
w:st=3D"on"><st1:PlaceType w:st=3D"on">University</st1:PlaceType> of <st1:P=
laceName
 w:st=3D"on">Utah</st1:PlaceName></st1:place> introduced a technique that m=
ay
significantly improve outcomes for T2b lesions.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In their series of 11 patients wit=
h T2b
lesions, they improved the 5-year disease free survival rate to 91% by
performing excision of the ipsilateral aryepiglottic fold and hemiepiglotti=
s before
excising the glottic specimen.<span style=3D'mso-spacerun:yes'>&nbsp; </spa=
n>This
had the effect of<span style=3D'mso-spacerun:yes'>&nbsp;
</span>&#8220;uncapping&#8221; the posterolateral paraglottic space and
allowing full exposure of the medial wall of the pyriform sinus and thyroid
cartilage from above.<span style=3D'mso-spacerun:yes'>&nbsp; </span>This is
merely an extension of the concept that adequate visualization of the tumor=
 during
endoscopic excision is vital.</p>

<p class=3DGRIndent-Normal>Moreau performed a retrospective study of 160 pa=
tients
treated from 1988 to 1996 to determine if laser endoscopic microsurgery is a
reliable and appropriate approach in the treatment of laryngeal cancers.<a
name=3D13></a><a name=3D14></a><span style=3D'mso-spacerun:yes'>&nbsp; </sp=
an>Glottic
tumors were treated with either type I, type II, or type III cordectomy, wi=
th
or without conservation of an inferior muscular band, and extended if neces=
sary
to all or part of the contralateral cord. For supraglottic cancers, an exci=
sion
limited to a part of the vestibule, a trans-preepiglottic resection, or a
radical supraglottic resection was carried out.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>They found that<a name=3D15></a> c=
orrected
actuarial survival at 5 years was 97% for the 98 infiltrative glottic tumors
and 100% for the 18 infiltrative supraglottic and 27 in situ carcinomas. No
local recurrences were noted, in either the group of 118 infiltrating cance=
rs
(in whom two precancerous lesions were treated with a further laser excisio=
n),
or in the 27 in situ carcinomas. Local control was thus 100%. One patient d=
ied
of his cancer, with lung metastases after neck recurrence.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>He concluded that, <a name=3D16></=
a>like
Steiner and Rudert, his series demonstrated the oncologic validity of this
surgical approach to the treatment of unadvanced glottic tumors. </p>

<p class=3DGRIndent-Normal>Gallo et al performed a retrospective study of 1=
51
patients treated from April 1982 to June to define when laser resection of
early-stage glottic carcinoma is indicated and to compare the results obtai=
ned
by laser surgery with other therapeutic options.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Glottic tumors were treated with t=
ype
III, type IV, and type Va cordectomies according to the classification of
endoscopic cordectomies proposed by the European Laryngological Society in
2000.</p>

<p class=3DGRIndent-Normal>They found that all patients with carcinoma in s=
itu
Tis were free of disease with local control rate at 3 years of 100%; 2 died=
 of
other causes without evidence of local recurrence with an overall survival =
rate
at 3 years of 83.2%. Of the 117 patients with stage T1a cancer, 110 are fre=
e of
disease at 3 years with local control rate of 94%; 4 patients died of other
causes without evidence of local recurrence with an overall survival rate of
96.5%. Of the 22 patients with stage T1b cancer, 20 are free of disease at 3
years with a local control rate of 91%; 1 patient died of other causes with=
out
evidence of local recurrence with an overall survival rate at 3 years of
95.4%.<span style=3D'mso-spacerun:yes'>&nbsp; </span>They concluded that
endoscopic laser surgery is an efficacious and cost-effective treatment for
early stage glottic cancer.</p>

<p class=3DGRIndent-Normal>Gallo et al also noted that the removal of 2 to =
5 mm
of healthy tissue surrounding the neoplastic lesion is the suggested
measurements in the current literature. They stated that a dilemma arises w=
hen
treating a tumor of the vocal cord, which extends to (T1a) or involves (T1b)
the anterior commissure. Under these circumstances, the removal of the ante=
rior
commissure, together with a variable portion of the contralateral vocal cor=
d,
can be helpful in obtaining safety margins. Therefore, they recommended tha=
t the
transmuscular cordectomy (type III) is indicated in cases of small superfic=
ial
tumors of the mobile vocal fold (T1a); the total cordectomy (type IV) is
indicated in cases of T1a cancer with extension to the anterior commissure,
and/or when the tumor involves the vocal fold in an infiltrative pattern an=
d/or
when the tumor size is more than 0.7 mm; the extended cordectomy encompassi=
ng
the contralateral vocal fold (type Va) is indicated in cases of T1b cancer
involving the anterior commissure or in horseshoe lesions.</p>

<p class=3DGRIndent-Normal>Most European authors advocate the CO2 laser
equivalent of vocal cord &#8220;stripping&#8221; for CIS and microinvasive
carcinoma.<span style=3D'mso-spacerun:yes'>&nbsp; </span>For CIS, a submuco=
sal
cordectomy is advocated; the plane of dissection is the superficial layer of
the lamina propria.<span style=3D'mso-spacerun:yes'>&nbsp; </span>For
microinvasive carcinoma, a subligamental or transmuscular cordectomy is
advocated; the plane of dissection is either between the vocal ligament and=
 the
vocalis muscle, or through the vocalis muscle (the key point being that at
least some vocalis muscle is left intact throughout the full thickness of t=
he
cord). <span style=3D'mso-spacerun:yes'>&nbsp;</span>They grant this may re=
sult
in &#8220;overtreatment&#8221; of many lesions, but this results in excelle=
nt
oncologic results while maintaining good voice outcomes.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In addition, CIS can be very diffi=
cult
to distinguish from microinvasive carcinoma, especially based upon a small
biopsy of mucosal tissue.<span style=3D'mso-spacerun:yes'>&nbsp; </span>(Of=
 note,
immunohistological staining for Epidermal Growth Factor receptors can help =
in
distinguishing moderate from severe dysplasia.)<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Most American authors feel that co=
ld
instrumentation, alone, is adequate for a plane of dissection superficial to
the vocal ligament.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The CO2 l=
aser
should be used for any transmuscular dissection.</p>

<p class=3DGR-Heading1>Endoscopic Management of Supraglottic Lesions</p>

<p class=3DGRIndent-Normal>Unlike glottic carcinoma, surgery is <i>usually<=
/i>
favored in the treatment of supraglottic squamous cell carcinoma unless pat=
ient
factors preclude surgery.<span style=3D'mso-spacerun:yes'>&nbsp; </span></p>

<p class=3DGRIndent-Normal>The major contraindications to <i>any </i>form of
supraglottic laryngectomy include </p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l2 level1 lfo1;
tab-stops:list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-font=
-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>1)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Involvement at the glottic level (Kirchner
demonstrated that extension into the infrapetiole/anterior commissure region
frequently results in thyroid cartilage invasion)</p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l2 level1 lfo1;
tab-stops:list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-font=
-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>2)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Invasion of the cricoid or thyroid cartilage=
</p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l2 level1 lfo1;
tab-stops:list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-font=
-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>3)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Involvement of the tongue base to within 1 c=
m of
the circumvallate papillae.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DGRIndent-Normal><st1:place w:st=3D"on"><st1:City w:st=3D"on">Vau=
ghan</st1:City></st1:place>
first described the CO2 laser for use in supraglottic squamous cell carcino=
ma
in 1978.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Since that time,
application of the laser to supraglottic cancer has gained wide acceptance =
in
Europe, but not so in the <st1:place w:st=3D"on"><st1:country-region w:st=
=3D"on">United
  States</st1:country-region></st1:place>.<span style=3D'mso-spacerun:yes'>=
&nbsp;
</span>Some reasons for this may be that the endoscopic approach involves an
entirely different treatment paradigm with which most American surgeons are=
 not
familiar.<span style=3D'mso-spacerun:yes'>&nbsp; </span>In addition, larger
lesions are technically more difficult to resect with the laser.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>And, finally, there has been a
proliferation of non-surgical organ preservation protocols in our country.<=
/p>

<p class=3DGRIndent-Normal>The key to use of the laser in the supraglottic =
region
is optimizing exposure.<span style=3D'mso-spacerun:yes'>&nbsp; </span>A big=
ger
area of exposure is required than for glottal surgery.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Steiner started to use a bivalved
laryngopharyngoscope in the 1980&#8217;s.<span style=3D'mso-spacerun:yes'>&=
nbsp;
</span>Zeitels later modified this while maintaining the bivalved design to
develop the presently popular supraglottiscope.<span
style=3D'mso-spacerun:yes'>&nbsp; </span></p>

<p class=3DGRIndent-Normal>Positioning works hand-in-hand with the scope to
maximize exposure.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The
Boyce-Jackson position is optimal:<span style=3D'mso-spacerun:yes'>&nbsp;
</span>extension occurs at the occipitoatlantic joint with the neck flexed =
on
the chest.</p>

<p class=3DGRIndent-Normal>Transoral laser resection is most successful when
supraglottic lesions are selected for small size and endoscopic
accessibility.<span style=3D'mso-spacerun:yes'>&nbsp; </span>The supraglott=
ic
lesions most amenable to laser resection are those that rest perpendicular =
to
the distal lumen of the supraglottiscope and therefore minimize tangential
cutting.<span style=3D'mso-spacerun:yes'>&nbsp; </span>These include</p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l0 level1 lfo2;
tab-stops:0pt list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-=
font-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>1)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Suprahyoid epiglottic lesions</p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l0 level1 lfo2;
tab-stops:0pt list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-=
font-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>2)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Lesions of the aryepiglottic fold</p>

<p class=3DMsoNormal style=3D'margin-left:36.0pt;text-indent:-18.0pt;mso-li=
st:l0 level1 lfo2;
tab-stops:0pt list 36.0pt'><![if !supportLists]><span style=3D'mso-fareast-=
font-family:
"Times New Roman"'><span style=3D'mso-list:Ignore'>3)<span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Lesions of the false vocal fold</p>

<p class=3DMsoNormal style=3D'margin-left:18.0pt;tab-stops:0pt'><o:p>&nbsp;=
</o:p></p>

<p class=3DGRIndent-Normal>Lesions of the infrahyoid epiglottis and upper F=
VC are
more difficult to resect.</p>

<p class=3DGRIndent-Normal>Following resection of the specimen, margin anal=
ysis
is best accomplished by sending the entire specimen for evaluation.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Decisions regarding radiation ther=
apy
and management of the necks should be based on the pathology of the primary
lesion.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Fears that this may r=
esult
in undesirable treatment delay of the necks should be alleviated by the fact
that laser resection can be performed as an excisional biopsy at the time of
staging endoscopy.</p>

<p class=3DGRIndent-Normal>In Zeitels series of 19 patients with T1 and T2N0
supraglottic lesions limited to sites 1-3 above, none of them failed in the
neck, no patient required artificial airway intervention, and most patients
returned to a normal diet within several days.<span
style=3D'mso-spacerun:yes'>&nbsp; </span></p>

<p class=3DGRIndent-Normal>Larger lesions in N0 patients are better served
post-excision by full-course XRT to the primary and bilateral necks, and th=
is
represents a more aggressive form of treatment than XRT alone, particularly=
 in
those patients who may not be good candidates for open surgery.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Even in these cases, clear margins=
 are
usually obtained at the time of laser excision because of the tendency of
supraglottic carcinoma to develop a pseudocapsule.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>In Zeitels series of 23 patients w=
ith T2
or T3N0 lesions treated with laser excision and XRT, 16/23 had clear margin=
s at
the primary site; none of these patients failed locally.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>However, of the 7 patients without=
 clear
margins, 4 experienced local failure requiring salvage total laryngectomy, =
and
another failed in the neck.<span style=3D'mso-spacerun:yes'>&nbsp; </span>In
general, completely excising the primary lesion prior to XRT is thought to =
result
in a 20-35% treatment advantage over XRT alone.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Though Steiner has used single-mod=
ality
endoscopic treatment for T2 and T3 lesions, most surgeons advocate
post-operative XRT because it is extremely difficult to guarantee comprehen=
sive
excision of the preepiglottic and paraglottic space.</p>

<p class=3DGRIndent-Normal>Ambrosch stated that comparing the results of
different treatments for early laryngeal carcinoma one may conclude that la=
ser
microsurgery is the method of choice for treatment of these tumors based on
oncologic, functional, and economic considerations. The published results,
however, indicate that approximately 70&#8211;80% of patients with pT2b and=
 pT3
glottic carcinomas remain free of local tumor recurrence, with minimal
morbidity and a functioning larynx. The results of laser microsurgery in
patients with moderately advanced supraglottic cancer are comparable to tho=
se
of open supraglottic laryngectomy with regard to local control and survival
rates. They are better than the results published for primary radiotherapy =
with
regard to local control and survival, and they are superior with respect to
organ preservation.</p>

<p class=3DGRIndent-Normal>Jones et al investigated were 488 patients with =
T1-2,
N0 squamous cell carcinoma of the larynx. Four hundred nineteen patients we=
re
treated by irradiation, and 69 were treated with surgery. Most surgical
patients were treated earlier in the series, whereas radiotherapy later bec=
ame
the treatment of choice. The primary outcome measures were recurrence at the
primary site, recurrence in the neck, and tumor-specific survival. The
secondary outcome measure was speech and voice quality. Surgery included
horizontal or vertical partial laryngectomy and various minor procedures on=
 the
glottis, including cordectomy. Over a 30-year period, radiotherapy was
administered to a dose of 60-66 Gy given over 30-33 daily fractions. </p>

<p class=3DGRIndent-Normal>They found that surgery tended to be performed e=
arly
on in the series and radiotherapy thereafter. Surgery was more likely to be
carried out for supraglottic disease. These differences apart, the radiothe=
rapy
and surgery groups of patients were well matched. The 5-year tumor-specific
survival for those treated by irradiation was 87% and for surgery it was 77=
% (p
=3D .1022). Glottic cancer and T1 disease were associated with high 5-year
survivals: 90% and 91%, respectively. Supraglottic site and T2 disease both=
 had
a poorer prognoses: 79% and 69%, respectively. The differences for both set=
s of
data were significant. There was no significant difference in primary site
recurrence rates for the two treatment modalities, but regional recurrence =
was
higher in the surgery group. Further analysis demonstrated that this was no=
t a
function of surgery per se but rather of the unit's policy toward the N0 ne=
ck
at the time surgery was carried out. Regarding speech and voice quality,
radiotherapy was far superior to surgery. All patients in the radiotherapy
group but only 3 of 10 in the surgery group were judged to have a good or
normal voice (p =3D .0017). <span
style=3D'mso-spacerun:yes'>&nbsp;&nbsp;</span>They concluded that both surg=
ery
and irradiation are equally effective at treating early laryngeal carcinoma.
Speech and voice were highly significantly better in patients treated by
irradiation than in those treated by surgery. </p>

<p class=3DGR-Heading1><a name=3D6></a><a name=3D12></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para42></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para44></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para48></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para49></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para63></a><a
name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec25_"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec25></a><a
name=3D"4-u1.0-B0-323-01985-4..50010-1--cesec26_"></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--cesec26></a><a
name=3D4-u1.0-B0-323-01985-4..50010-1--para67></a>Conclusions</p>

<p class=3DGRIndent-Normal>Microendoscopic laser surgery provides an excell=
ent
alternative to radiotherapy in the treatment of early-stage glottic cancer.
Since its introduction by Strong and Jako in 1972, CO<sub>2</sub> laser has
found wide acceptance in the treatment of laryngeal diseases. The advantage=
s of
laser resection include minimal bleeding, precise control of resection, and=
 the
absence of postoperative edema. Cure rates of patients with early-stage glo=
ttic
carcinoma treated with CO<sub>2</sub> laser are equal to those achieved with
radiation therapy.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Neverthele=
ss,
the role and the indications of this technique in the treatment of early-st=
age
glottic cancer has not been defined accurately and remains controversial.</=
p>

<p class=3DGR-Heading1>Discussion</p>

<p class=3DGRHeading2>Discussant's Remarks by Charles Vaughan, M.D.:</p>

<p class=3DGRArial10B>I am impressed and pleased and ask that you pass on to
Camysha Wright, MD, my congratulations for a job well done. It was an excel=
lent
discussion of published literature. <span
style=3D'mso-spacerun:yes'>&nbsp;</span>Perhaps some further experience mig=
ht
also be of interest .<span style=3D'mso-spacerun:yes'>&nbsp; </span>It is
unpublished because there is no way to describe it in &quot;scientific&quot;
terms, the problem being that of field cancerization, a common phenomenon in
the glottis. &nbsp;As a &quot;for instance&quot;, a heavy equipment operator
who worked in his enclosed cab and continuously smoked, was referred follow=
ing
failed xrt for T1 scca RTVF. This was easily managed with the CO2 laser;
however in a few months he had a lesion on the opposite fold, again, easily
managed, only &nbsp;later to show a new lesion on the right fold, a few mm
anterior to the first.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Well, =
to
make short, over the next 12 years we managed 13 such &quot;early&quot; can=
cers
arising in his &quot;sick mucosa&quot;. During this time he <span
style=3D'mso-spacerun:yes'>&nbsp;</span>continued to smoke- and to talk and=
 to
eat normally. He died of lung cancer.<span style=3D'mso-spacerun:yes'>&nbsp;
</span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></=
p>

<p class=3DGRArial10B>How do you determine cure rates when dealing with both
synchronous and metachronous cancers? The above story is extreme, but the
problem <span style=3D'mso-spacerun:yes'>&nbsp;</span>is common. Our experi=
ence
at &nbsp;VAMC <st1:place w:st=3D"on"><st1:City w:st=3D"on">Boston</st1:City=
></st1:place>
is a metachronous rate of 5%/year! and the question becomes this: is a furt=
her
appearance of cancer new disease or old? And how can it be reported? I have
been at this since the late 1960's and still can't figure it out. <span
style=3D'mso-spacerun:yes'>&nbsp;&nbsp;</span>(And this might also give you=
 pause
when you read reports of cure rates by others).<span
style=3D'mso-spacerun:yes'>&nbsp; </span>My experience also includes meticu=
lous
histologic evaluation of every excised specimen, jointly with the pathologi=
st,
and this has led me to the conclusion that a widely applied carcinogen (tob=
acco
) has wide affect. All exposed mucosa become sick, and given time develops =
cancer.
Unfortunately, we have no cure for this. Yes, we can remove the dangerously
atypical cells, and the laser does this nicely, but attempting more than th=
is does
not improve things. It only creates morbidity.</p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></=
p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;font-family:Arial'>So this is the advantage of the
laser/microscope combo: because the field is dry and magnified, the surgeon
(with experience) can actually SEE cancerous tissue; and only it need be
removed. (if all the cancer is removed, what is the advantage of a 5mm marg=
in?
Or any margin) <o:p></o:p></span></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></=
p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;font-family:Arial'>Charles W Vaughan MD<br>
<st1:place w:st=3D"on"><st1:PlaceName w:st=3D"on">Boston</st1:PlaceName> <s=
t1:PlaceType
 w:st=3D"on">University</st1:PlaceType> <st1:PlaceType w:st=3D"on">School</=
st1:PlaceType></st1:place>
of Medicine </span></b><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:10.0pt;mso-fareast-language:EN-US'><o:p></o:p></span></b=
></p>

<b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:14.0pt;
mso-bidi-font-size:10.0pt;font-family:Arial;mso-fareast-font-family:"Times =
New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DGR-Heading1>References</p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto'><span
style=3D'color:black'>Ambrosch, P.</span><span style=3D'font-family:Verdana;
color:black'><span style=3D'mso-spacerun:yes'>&nbsp; </span></span><span
style=3D'color:black;mso-bidi-font-weight:bold'>The role of laser microsurg=
ery in
the treatment of laryngeal cancer.</span><span style=3D'font-family:Verdana;
color:black'> </span><span style=3D'color:black'>Current Opin Otolaryngol H=
ead
Neck Surg 2007, 15:82-88.<span style=3D'mso-bidi-font-weight:bold'><o:p></o=
:p></span></span></p>

<p class=3DMsoNormal>Bailey BJ. Vertical Partial Laryngectomy. <u>Atlas of =
Head
&amp; Neck Surgery &#8211; Otolaryngology</u>. 2nd Edition. Lippincott,
Williams &amp; Wilkins. 2001. Pages 184-187.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Bailey BJ. Early Glottic Carcinoma. <u>Head &amp; Neck
Surgery &#8211; Otolaryngology</u>. 2nd Edition. Lipincott-Raven. 1998. Pag=
es
1703-1724.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Cummings, C. Laser Surgery: Basic principles and safety
considerations. Chapter 7. Otolarygology Head and Neck Surgery, 4<sup>th</s=
up>
edition. </p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Damm M,=
 Sittel C,
et al. </span>Transoral CO2 Laser for Surgical Management of Glottic Carcin=
oma
in Situ. <i>Laryngoscope</i>. Volume 110. Number 7. July 2000. Pages 1215-1=
221.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><st1:place w:st=3D"on"><st1:City w:st=3D"on">Davis</st=
1:City></st1:place>
RK. Endoscopic Surgical Management of Glottic Laryngeal Cancer. <i>Otolaryn=
gologic
Clinics of <st1:place w:st=3D"on">North America</st1:place>. </i>Volume 30.
Number 1. February 1997. Pages 79-86.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Desanto LW. Supraglottic Laryngectomy. <u>Head &amp; N=
eck
Surgery &#8211; Otolaryngology</u>. 2nd Edition. Lipincott-Raven. 1998. Pag=
es
1725-1738.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Eckel EH, Thumfart W, Jungehulsing M, Sittel C, Stenne=
rt E.
Transoral laser surgery for early glottic carcinoma. Eur Arch Otolaryngol 2=
000;
257: 221&#8211;226.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><st1:place w:st=3D"on"><st1:City w:st=3D"on">Flint</st=
1:City></st1:place>
PW. Minimally Invasive Techniques for Management of Early Glottic Cancer. <=
i>Otolaryngologic
Clinics of <st1:place w:st=3D"on">North America</st1:place>. </i>Volume 35.=
 2002<i>.
Pages 1055-1066.</i></p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Gallo A, de Vincentiis M. CO2 Laser Cordectomy for
Early-Stage Glottic Carcinoma: A Long-Term Follow-up of 156 Cases. <i>Laryn=
goscope</i>.
Volume 112. Number 2. February 2002. Pages 370-374.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Gallo A=
, Mocetti
P, De Vincentiis M, et al. </span>Neoplastic infiltration of laryngeal
cartilages: histocytochemical study. Laryngoscope 1992; 102: 891&#8211;895.=
 </p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Gallo A, et al.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>CO<sub>2</sub> Laser Cordectomy for Early-Stage Glottic Carcinoma: A
Long-Term Follow-up of 156 Cases.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Laryngoscope.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Volume
112(2),&nbsp;February 2002,&nbsp;pp 370-374.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Hirano M, Hirade Y, Kawasaki H. Vocal function followi=
ng
carbone dioxide laser surgery for glottic carcinoma. Ann Otol Rhinol Laryng=
ol
1985; 94: 232&#8211;235.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>J&auml;ckel MC, Martin A,<span
style=3D'mso-spacerun:yes'>&nbsp; </span>and Steiner W.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Twenty five years experience with =
laser
surgery for head and neck tumors.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Report of an international symposium.<span
style=3D'mso-spacerun:yes'>&nbsp; </span><st1:place w:st=3D"on"><st1:City w=
:st=3D"on"><span
  style=3D'color:#444444;mso-bidi-font-weight:bold'>G&ouml;ttingen</span></=
st1:City><span
 style=3D'color:#444444;mso-bidi-font-weight:bold'>, <st1:country-region w:=
st=3D"on">Germany</st1:country-region></span></st1:place><span
style=3D'color:#444444;mso-bidi-font-weight:bold'>, 2005.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Eur Arch Otorhinolaryngol (2007) 2=
64:
577-585.</span></p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Johnson JT, Curtin H. Carcinoma of the Supraglottic La=
rynx. <i>SIPAC.
</i>Second Edition. <st1:place w:st=3D"on"><st1:PlaceName w:st=3D"on">Ameri=
can</st1:PlaceName>
 <st1:PlaceType w:st=3D"on">Academy</st1:PlaceType></st1:place> of Otolaryn=
gology
&#8211; Head and Neck Surgery Foundation, Inc. 2000.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal><st1:place w:st=3D"on"><st1:City w:st=3D"on">Jones</st=
1:City> <st1:State
 w:st=3D"on">AS</st1:State></st1:place>, et al.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Treatment of early laryngeal cance=
rs
(T1-T2 N0): surgery or irradiation.<span style=3D'mso-spacerun:yes'>&nbsp;
</span>Head and Neck.<span style=3D'mso-spacerun:yes'>&nbsp; </span>Vol 26,=
 Issue
2, pages 127-135.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Moreau PR. Treatment of laryngeal carcinomas by laser
endoscopic microsurgery. Laryngoscope 2000; 110: 1000&#8211;1006</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Myers EN, Wagner RL, Johnson JT. Microlaryngoscopic su=
rgery
for T1 glottic lesions: a cost-effective option. Ann Otol Rhinol Laryngol 1=
994;
103: 28&#8211;30. </p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>R Osguthorpe JD, Putney FJ. Open Surgical Management of
Early Glottic Carcinoma. <i>Otolaryngologic Clinics of <st1:place w:st=3D"o=
n">North
 America</st1:place>. </i>Volume 30. Number 1. February 1997. Pages 87-99.<=
/p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Rebeiz EE, Wang Z, Annino DJ, et al. Preliminary clini=
cal
results of window partial laryngectomy: a combined endoscopic and open
technique. Ann Otol Rhinol Laryngol 2000; 109: 123&#8211;127.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Rydell R, Schalen L, Fex S, Elner A. Voice evaluation =
before
and after laser excision vs radiotherapy of T1a glottic carcinoma. Acta
Otolaryngol 1995; 115: 560&#8211;565. </p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Shapshay SM, Wang Z, Rebeiz EE, et al. &#8216;Window&#=
8217;
laryngoplasty: a new combined laser endoscopic and open technique for conse=
rvation
surgery. </p>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Simpson=
 CB,
Postma GN, et al. </span>Speech Outcomes After Laryngeal Cancer Management.=
 <i>Otolaryngologic
Clinics of <st1:place w:st=3D"on">North America</st1:place>. </i>Volume 30.
Number 1. February 1997. Pages 189-205.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Tufano RP. Organ Preservation Surgery for Laryngeal Ca=
ncer. <i>Otolaryngologic
Clinics of <st1:place w:st=3D"on">North America</st1:place>. </i>Volume 35.=
 2002.
Pages 1067-1080.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Zeitels SM. Surgical Management of Early Supraglottic
Cancer. <i>Otolaryngologic Clinics of <st1:place w:st=3D"on">North America<=
/st1:place></i>.
Volume 30. Number 1. February 1997. Pages 59-78.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal>Zeitels SM, Shapshay SM. Endoscopic Management of Glot=
tic
Cancer. <i>SIPAC</i>. First Edition. <st1:place w:st=3D"on"><st1:PlaceName =
w:st=3D"on">American</st1:PlaceName>
 <st1:PlaceType w:st=3D"on">Academy</st1:PlaceType></st1:place> of Otolaryn=
gology
&#8211; Head and Neck Surgery Foundation, Inc. 2002.</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>
